Research programme: anti-cancer therapeutics - OncoRx Pharmaceuticals

Drug Profile

Research programme: anti-cancer therapeutics - OncoRx Pharmaceuticals

Alternative Names: ORX 101; ORX 102; ORX 103; Tumour-activated nanodrug programme - OncoRx

Latest Information Update: 05 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer OncoRx Pharmaceuticals Inc
  • Class Antineoplastics; Phenothiazines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Integrin alpha4beta1 modulators; P-glycoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 02 Dec 2015 OncoRx Pharmaceuticals has patent protection for its drugs for the treatment of therapy-resistant malignant tumours in USA
  • 19 Oct 2015 OncoRx Pharmaceuticals plans preclinical trials for Glioma and glioblastoma
  • 23 Sep 2015 Research programme: anti-cancer therapeutics - OncoRx Pharmaceuticals is available for licensing in World as of 19 Oct 2015. www.oncorxpharmaceuticalscom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top